Association of Antioxidant to the Genesis of Psychiatric Disorder

Ranjit S. Ambad¹, Sonal Muley², Lata Kanyal Butola³*, Ajinkya S. Ghogare⁴

¹Department of Biochemistry, Datta Meghe Medical College, Shalinitai Meghe Hospital & Research Centre, Hingana, Nagpur-441110, Maharashtra, India
²Department of Ophthalmology, Datta Meghe Medical College, Shalinitai Meghe Hospital & Research Centre, Hingana Nagpur-441110, Maharashtra, India
³Department of Biochemistry, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha-442001, Maharashtra, India
⁴Department of Psychiatry, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi, Wardha-442001, Maharashtra, India

**Article History:**
Received on: 09 Oct 2020
Revised on: 29 Oct 2020
Accepted on: 18 Nov 2020

**Keywords:**
Mental disorder, Depresion, Oxidative stress, Antioxidant status, SOD

| ABSTRACT |
| --- |

Mental disorders were associated with a wide range of chronic illnesses, disability, and even mortality, particularly among elderly people. Depression will be the second cause of disease. Anxiety is an emotional state of antipathy in which the sense of fear is disproportionate to the magnitude of the risk. Enzymatic antioxidants like SOD, GPx, and non-enzymatic antioxidants such as vitamin C, E act as free scavengers, thereby reducing oxidative stress and resulting in cell injury. Thus, we aimed to study SOD, GPx, Vitamin C, and Vitamin E. 1. To study levels of SOD, GPx, Vitamin C, and Vitamin E in psychiatric disorders. 2. To study the levels of Vit-C and E before and after vitamin supplementations. To correlate the levels of SOD, GPx, Vitamin C, and Vitamin E between psychiatric patients and healthy controls (age-matched) attending AVBRH Wardha and SMHRC Nagpur. This cross-sectional examination was completed on 50 psychiatric patients and 50 healthy controls and the levels of SOD, GPx, Vitamin C, and Vitamin E are measured before and after giving supplements. In Psychiatric patients, Superoxide dismutase (SOD) levels were 135.26±24.68, Glutathione Peroxidase levels were 1.591±3.35, Vitamin C levels were 0.32±0.11 and Vitamin E levels were 4.302±1.54, which is lower than the normal range. The present study concludes that antioxidant plays a major role to fight against oxidative stress. So proper antioxidant should be taken.

**INTRODUCTION**

Mental disorders were associated with a wide range of chronic illnesses, Alcohol usage disruptions, disability, and even mortality, particularly among elderly people (Patel et al., 2018). Depression will be the second cause of disease identified by the WHO in 2020 (World Health Organization, 2017). The risk of suicide rises with depression (Behere et al., 2017). Anxiety is an emotional state of antipathy in which the sense of fear is disproportionate to the magnitude of the risk. In certain psychological conditions, anxiety is involved (Weinberger, 2001). About one-
eighth of the total population worldwide have excessive anxiety (Eisenberg et al., 1990).

Oxidative stress arises when the reactive oxygen species (ROS) are overproduced, or the cellular antioxidant defense mechanisms are deficient (Berg et al., 2004; Kohen and Nyska, 2002). Maternal antioxidant protection mechanism, which through enzymatic induction counteracts the effects of free radicals, may prevent nitrosative stress (Gaikwad et al., 2017).

Accumulating evidence indicates heightened oxidative stress could be involved in schizophrenia pathophysiology (Steuillet et al., 2017; Yao and Reddy, 2011). Schizophrenia is a psychiatric illness that weakens and affects around one per cent of the people. It is described by positive side effects (e.g., irregular attitudes and thinking), negative side effects (e.g. inability to feel pleasure and detachment from society), and impairment mental processes (Bitanhirwe and Woo, 2011). In its etiology, it is considered as multifactorial and heterogeneous, so that various pathological processes converge on a cluster of allied symptoms. Schizophrenia and other psychotic disorders are generally known as neurodevelopmental disorders, where several hits mount up throughout the crucial phase of development of CNS triggering the disorders (Hovatta et al., 2010; Valko et al., 2007). Most schizophrenic sufferers begin with a prodromal process marked by subclinical symptoms of the condition, which we will con signed to after this clinically elevated psychosis risk state (Hassan et al., 2014; Inoguchi, 2003).

In some trials, 22% of those who meet the CHR criterion lead to a year of record psychotic illness, compared with 0.015% healthy individuals (Xu et al., 2014). Neurons are usually less resistant to free radical attacks and damaged antioxidant systems or disclosure to free radicals can cause destructive reactions with substrates critical for the continued existence of cells such as proteins, lipids, nucleic acids and lead to neuronal death (McDaniel, 1995; Lohr, 1991). Freshly, OS has involved and evidence is emerging to hold the role it plays in bipolar disorder (Cheeseman and Slater, 1993; Jesberger and Richardson, 1991).

SOD and GPx form an antioxidant protection mechanism next to essential harm and defend against damage to the cells and molecules (Andrezza et al., 2007; Selek et al., 2008). Oxidative stress typically results from excessive development of reactive oxygen species (ROS) or failure of the ROS controlling enzymatic and non-enzymatic processes (Savas et al., 2006; Kensler et al., 1983). The cause of multiple physical and mental disorders is responsible for oxidative stress. To counter the oxidative stress, the body has its antioxidant system, which tries to control the oxidative injury. ROS and reactive nitrogen species are the two main mechanisms that control oxidative activity in the body (Cotgreave et al., 1988; Wendel et al., 1980).

Excessive development of ROS in the body leads to further oxidative stress, resulting in loss of intracellular signalling and cellular ageing leading to apoptosis (Cotgreave et al., 1988). Antioxidants like SOD, GPx, CAT, and non-antioxidants such as vitamin A, C, E, β-carotene, zinc, copper, selenium, and flavonoids act as free-scavengers, thereby reducing oxidative stress and resulting in cell injury (Riecher et al., 1989; Häfner et al., 1992). Reduced levels of Vit-C and E may not be adequate to fight ROS (Wasnik and Akarte, 2017).

A large proportion of the disorder has not been diagnosed by primary care doctors. Appropriate attention to psycho-neuro-endocrinological problems may help clinicians develop a more reliable and holistic view of patients and improve the likelihood of delivering the most appropriate care (Ambad et al., 2020a). This highlights the need for more training to enhance early detection at this stage (Pal et al., 2018). Knowledge of the endocrine system and minerals are important for the proper treatment of psychiatric disorders (Ambad et al., 2020b,c).

In this study, we have observed levels of SOD, GPx, Vitamin C, and Vitamin E.

Aim and Objective

Aim

1. To study levels of SOD, GPx, Vitamin C, and Vitamin E in psychiatric disorders.
2. To study the levels of Vit-C and E before and after vitamin supplementations.

Objective

To correlate the levels of SOD, GPx, Vitamin C, and Vitamin E between psychiatric patients and healthy controls (age-matched) attending AVBRH Wardha and SMHRC Nagpur.

MATERIALS AND METHODS

The current study was done in the Department of Biochemistry and Dept. of Psychiatry at Datta Meghe Medical College, Shalinitai Meghe Hospital &Research Centre, Nagpur in collaboration with Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences, Sawangi (Meghe) Wardha Maharashtra.

Total of 100 subjects was selected for the study. Out of which 50 patients are age and gender-matched.
healthy control, 50 were suffered from psychiatric disorders. Informed consent was taken from all participants included in the study.

**Sample Collection**

Blood sample was collected and all patients and controls (n=100) gave informed consent for participation to the study.

**GPx Measurement**

GSH-Px movement was estimated by the strategy for Paglia and Valentine. The enzymatic response was started by adding H2O2 to the reaction mixture containing decreased GSH, diminished nicotinamide adenine dinucleotide phosphate and GR. The adjustment in the absorbance at 340 nm was checked by Shimadzu UV 1601 spectrophotometer. One unit of GSH-Px is characterized as micromoles of NADPH oxidized every moment. Action was given in units per liter plasma volume (Pal et al., 2018).

**SOD Measurement**

SOD was resolved by the technique for Sun and partners. One unit of SOD was characterized as the measure of compound causing half inhibition in the NBT decrease rate. Activity was given in units per liter plasma volume (Ambad et al., 2020c).

**Estimation of vitamin C**

Vitamin C was estimated by HPLC with electrochemical or ultraviolet light exposure (Ambad et al., 2020b).

**Estimation of vitamin E**

Vitamin E was estimated by Modified simple method by baker and frank method and the technique by using 2,2'-bipyridyl, FeCl3 and C8H10. The complex of Fe+2 generated in this reaction with 2,2'-bipyridyl is determined by using a plain ELISA microplate at 492 nm (Paglia and Valentine, 1967).

**Inclusion Criteria**

1. Anxiety disorders
2. Panic disorders
3. Social phobia
4. Depression
5. Bipolar disorders

**Statistical Analysis**

All approximate findings were as mean ±SD. Mean values are determined by unpaired Student –t-test for meaning. Statistical analysis will be carried out using the Social Science software Statistical Kit (SPSS, 24.0). The categorical indicators would be used with frequencies and percentages. Probability values p < 0.05 is known as statistically important.

**OBSERVATION AND RESULTS**

**Table 1** showed the levels of Antioxidants in Psychiatric patients was highly significant than the normal control group.

There is a significant correlation between vitamins in psychiatric patients and healthy controls with a p-value of <0.05 shown in Table 2.

Table 3 showed after the supplementation with different doses of vitamins, there is a slight increase in the values of Vitamins. There is a significant correlation between vitamins in psychiatric patients before and after supplementation with a p-value of <.05.

**DISCUSSION**

In a healthy being, the development and a variety of interactions with free radicals are closely regulated by enzymatic defence mechanisms such as SOD, GPx, or via the role of non-enzymatic antioxidants such
Table 1: Levels of Antioxidants in Psychiatric patients and Healthy control

| Antioxidants              | Cases Mean±SD (n=50) | Controls Mean±SD (n=50) |
|---------------------------|---------------------|------------------------|
| Superoxide dismutase (SOD)| 135.26±24.68        | 178.5±38.48            |
| Glutathione Peroxidase   | 1.591±3.35          | 3.564±2.24             |
| Vitamin C                | 0.32±0.11           | 0.92±0.95              |
| Vitamin E                | 4.302±1.54          | 6.69±10.35             |

Table 2: Correlation of Antioxidant levels between cases and control

| Antioxidants              | Cases Mean±SD (n=50) | Controls Mean±SD (n=50) | t-value | p-value |
|---------------------------|---------------------|------------------------|---------|---------|
| Superoxide dismutase (SOD)| 135.26±24.68        | 178.5±38.48            | 6.688   | 0.0001  |
| Glutathione Peroxidase   | 1.591±3.35          | 3.564±2.24             | 3.462   | 0.0008  |
| Vitamin C                | 0.32±0.11           | 0.92±0.95              | 4.436   | 0.0001  |
| Vitamin E                | 4.302±1.54          | 6.69±10.35             | 1.614   | 0.1098  |

Table 3: Correlation of Antioxidant status before and after supplementation in psychiatric patients

| Antioxidant Status | Before Supplementation | After Supplementation | Vitamin Doses | t value | P-value |
|--------------------|-----------------------|----------------------|---------------|---------|---------|
| Vitamin E          | 4.302±1.54            | 5.526±2.97           | 400IU/day     | 2.587   | 0.0111  |
| Vitamin C          | 0.32±0.11             | 0.66±0.56            | 500mg/day     | 4.213   | 0.0001  |

CONCLUSIONS

The result of this study indicates that, in psychiatric disorders, the serum levels of SOD, GPx, Vit-C and Vit-E decrease, Low level of vit-C and E levels can not suffice to counter ROS and the level of antioxidant in the serum has been compromised to fight oxidative stress.

Antioxidants supplementation has provided some positive results in the treatment of neuropsychiatric disorders. These findings indicate that antioxidants should be studied either as an alternative therapy or as an adjunct to traditional medications, telepsychiatry diagnosis method has the ability to allow correctly and effectively diagnose psychological condi-
tions antioxidants are usually extremely low chance drugs and their use may before effective compared to the medicines that have been developed.

**Funding Support**

The authors declare that they have no funding support for this study.

**Conflict of Interest**

The authors declare that they have no conflict of interest for this study.

**REFERENCES**

Ambad, R. S., Butola, L. K., Singh, B. R., Bankar, N., Ghogare, A. S., Patil, R. 2020a. A Cross-Sectional Comparison of Minerals in Psychiatric Disorder. *International Journal of Psychosocial Rehabilitation*, 24:5968–5976.

Ambad, R. S., Jha, R. K., Bankar, N., Singh, B. R., Ghogare, A. S., Patil, A. R. 2020b. A Cross-Sectional Comparison of Serum Hormone (FSH, TSH, GH) Concentrations in Untreated Patients With Psychiatric Disorder. *International Journal of Psychosocial Rehabilitation*, 24:5960–5967.

Ambad, R. S., Jha, R. K., Bankar, N., Singh, B. R., Ghogare, A. S., Patil, R. 2020c. Role of Prolactin and Thyroid Hormone in Psychiatric Disorders. *International Journal of Psychosocial Rehabilitation*, 24:6001–6005.

Andreazza, A. C., Cassini, C., Rosa, A. R., Leite, M. C., Almeida, L. M. V. D., Nardin, P., Gonçalves, C. A. 2007. Serum S100B and antioxidant enzymes in bipolar patients. *Journal of Psychiatric Research*, 41(6):523–529.

Behera, P. B., Kumar, K., Behera, A. P. 2017. Depression: Why to talk? *Indian J Med Res*, 145(4):411–413.

Berg, D., Youdim, M. B. H., Riederer, P. 2004. Redox imbalance. *Cell and Tissue Research*, 318(1):201–213.

Bitanihirwe, B. K., Woo, T.-U. W. 2011. Oxidative stress in schizophrenia: An integrated approach. *Neuroscience & Biobehavioral Reviews*, 35(3):878–893.

Cheeseman, K. H., Slater, T. F. 1993. An introduction to free radical biochemistry. *British Medical Bulletin*, 49(3):481–493.

Cotgreave, I. A., Moldeus, P., Orrenius, S. 1988. Host Biochemical Defense Mechanisms Against Prooxidants. *Annual Review of Pharmacology and Toxicology*, 28(1):189–212.

Eisenberg, D. M., Davis, R. B., Ettner, S. L., Appel, S., Wilkey, S., Rompoy, M. V., Kessler, R. C. 1990. Trends in Alternative Medicine Use in the United States. *JAMA*, 280(18):1569–1569.

Gaikwad, K. B., Joshi, N. G., Selkar, S. P. 2017. Study of Nitrosative Stress in Pregnancy Induced Hypertension. *J Clin Diagn Res*, 11(3):6–08.

Häfner, H., Riecher-Rössler, A., Hambrecht, M., Maurer, K., Meisner, S., Schmidtke, A., Fäktkenheuer, B., Löfler, W., van der Heiden, W. 1992. IRAOS: an instrument for the assessment of onset and early course of schizophrenia. *Schizophrenia Research*, 6(3):209–223.

Hassan, W., Silva, C. B., Mohammadzai, I. U., da Rocha, J. T., Landeira-Fernandez, J. 2014. Association of Oxidative Stress to the Genesis of Anxiety: Implications for Possible Therapeutic Interventions. *Current Neuropharmacology*, 12(2):120–139.

Hovatta, I., Juhila, J., Donner, J. 2010. Oxidative stress in anxiety and comorbid disorders. *Neuroscience Research*, 68(4):261–275.

Inoguchi, T. 2003. Protein Kinase C-Dependent Increase in Reactive Oxygen Species (ROS) Production in Vascular Tissues of Diabetes: Role of Vascular NAD(P)H Oxidase. *Journal of the American Society of Nephrology*, 14(90003):227S–232.

Jargar, J. G., Hattiwale, S. H., Das, S., Dhundasi, S. A., Das, K. K. 2012. A modified simple method for determination of serum α-tocopherol (vitamin E). *Journal of Basic and Clinical Physiology and Pharmacology*, 23(1):45–53.

Jesberger, J. A., Richardson, J. S. 1991. Oxygen Free Radicals and Brain Dysfunction. *International Journal of Neuroscience*, 57(1-2):1–17.

Kensler, T., Bush, D., Kozumbo, W. 1983. Inhibition of tumor promotion by a biomimetic superoxide dismutase. *Science*, 221(4605):75–77.

Kohen, R., Nyska, A. 2002. Invited Review: Oxidation of Biological Systems: Oxidative Stress Phenomena, Antioxidants, Redox Reactions, and Methods for Their Quantification. *Toxicologic Pathology*, 30(6):620–650.

Lohr, J. B. 1991. Oxygen Radicals and Neuropsychiatric Illness. *Archives of General Psychiatry*, 48(12):1097–1097.

McDaniel, J. S. 1995. Depression in Patients With Cancer. *Archives of General Psychiatry*, 52(2):89–89.

Paglia, D. E., Valentine, W. N. 1967. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. *The Journal of Laboratory and Clinical Medicine*, 70(1):158–169.
Pal, S., Oswal, R., Vankar, G. 2018. Recognition of major depressive disorder and its correlates among adult male patients in primary care. *Archives of Psychiatry and Psychotherapy*, 20(3):55–62.

Patel, T., Brahmbhatt, M., Vankar, G. 2018. Prevalence of alcohol use disorders in hospitalised male patients. *Archives of Psychiatry and Psychotherapy*, 20(4):47–55.

Powers, S. K., Deruisseau, K. C., Quindry, J., Hamilton, K. L. 2004. Dietary antioxidants and exercise. *Journal of Sports Sciences*, 22(1):81–94.

Riecher, A., Maurer, K., Löffler, W., Fätkenheuer, B., Heiden, W., Hafner, H. 1989. Schizophrenia — a disease of young single males? *European Archives of Psychiatry and Neurological Sciences*, 239(3):210–212.

Robitaille, L., Hoffer, L. J. 2015. A simple method for plasma total vitamin C analysis suitable for routine clinical laboratory use. *Nutrition Journal*, 15(1).

Savas, H. A., Gergerlioglu, H. S., Armutcu, F., Herken, H., Yilmaz, H. R., Kocoglu, E., Sele, S., Tutkun, H., Zoroglu, S. S., Akyol, O. 2006. Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: Impact of past episodes. *The World Journal of Biological Psychiatry*, 7(1):51–55.

Selek, S., Savas, H. A., Gergerlioglu, H. S., Bulbul, F., Uz, E., Yumru, M. 2008. The course of nitric oxide and superoxide dismutase during treatment of bipolar depressive episode. *Journal of Affective Disorders*, 107(1-3):89–94.

Steullet, P., Cabungcal, J. H., Coyle, J., Didriksen, M., Gill, K., Grace, A. A., Hensch, T. K., LaMantia, A. S., Lindemann, L., Maynard, T. M., Meyer, U., Morishita, H., O’Donnell, P., Puhl, M., Cuenod, M., Do, K. Q. 2017. Oxidative stress-driven parvalbumin interneuron impairment as a common mechanism in models of schizophrenia. *Molecular Psychiatry*, 22(7):936–943.

Sun, Y., Oberley, L. W., Li, Y. 1988. A simple method for clinical assay of superoxide dismutase. *Clinical Chemistry*, 34(3):497–500.

Traber, M. G., Stevens, J. F. 2011. Vitamins C and E: Beneficial effects from a mechanistic perspective. *Free Radical Biology and Medicine*, 51(5):1000–1013.

Valko, M., Leibfritz, D., Moncol, J., Cronin, M. T., Mazur, M., Telser, J. 2007. Free radicals and antioxidants in normal physiological functions and human disease. *The International Journal of Biochemistry & Cell Biology*, 39(1):44–84.

Wasnik, R. R., Akarte, N. R. 2017. Evaluation of Serum Zinc and Antioxidant Vitamins in Adolescent Homozygous Sickle Cell Patients in Wardha, District of Central India. *Journal of Clinical and Diagnostic Research*, 11(8):1–03.

Weinberger, D. R. 2001. Anxiety at the Frontier of Molecular Medicine. *New England Journal of Medicine*, 344(16):1247–1249.

Wendel, A., Jakoby, W. B., Bend, J. R., Caldwell, J. 1980. Glutathione peroxidase. Enzymatic Basis of Detoxication. pages 333–348, New York. Academic Press.

World Health Organization 2017. Depression and other common mental disorders: global health estimates. Page No: 24.

Xu, Y., Wang, C., Klabnik, J., Donnell, J. O. 2014. Novel Therapeutic Targets in Depression and Anxiety: Antioxidants as a Candidate Treatment. *Current Neuropharmacology*, 12(2):108–119.

Yao, J. K., Reddy, R. 2011. Oxidative Stress in Schizophrenia: Pathogenetic and Therapeutic Implications. *Antioxidants & Redox Signaling*, 15(7):1999–2002.